Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 336

The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline

Rathmell, W. Kimryn, Rumble, R. Bryan, Van Veldhuizen, Peter J., Al-Ahmadie, Hikmat, Emamekhoo, Hamid, Hauke, Ralph J., Louie, Alexander V., Milowsky, Matthew I., Molina, Ana M., Rose, Tracy L., Siva, Shankar, Zaorsky, Nicholas G., Zhang, Tian, Qamar, Rubina, Kungel, Terry M., Lewis, Bryan, Singer, Eric A.·2022·Journal of Clinical Oncology
DOI 10.1200/jco.22.00868
Open this paper in CoChat — free account

Abstract

PURPOSE: To provide recommendations for the management of patients with metastatic clear cell renal cell carcinoma (ccRCC). METHODS: An Expert Panel conducted a systematic literature review to obtain evidence to guide treatment recommendations. RESULTS: The panel considered peer-reviewed reports published in English. RECOMMENDATIONS: The diagnosis of metastatic ccRCC should be made using tissue biopsy of the primary tumor or a metastatic site with the inclusion of markers and/or stains to support the diagnosis. The International Metastatic RCC Database Consortium risk criteria should be used to inform treatment. Cytoreductive nephrectomy may be offered to select patients with kidney-in-place and favorable- or intermediate-risk disease. For those who have already had a nephrectomy, an initial period of active surveillance may be offered if they are asymptomatic with a low burden of disease. Patients with favorable-risk disease who need systemic therapy may be offered an immune checkpoint inhibitor (ICI) in combination with a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI); patients with intermediate or poor risk should be offered a doublet regimen (no recommendation was provided between ICIs or an ICI in combination with a VEGFR TKI). For select patients, monotherapy with either an ICI or a VEGFR TKI may be offered on the basis of comorbidities. Interleukin-2 remains an option, although selection criteria could not be identified. Recommendations are also provided for second- and subsequent-line therapy as well as the treatment of bone metastases, brain metastases, or the presence of sarcomatoid features. Participation in clinical trials is highly encouraged for patients with metastatic ccRCC. Additional information is available at www.asco.org/genitourinary-cancer-guidelines

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.22.00868

Cites

120 of 120 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 120 references

Cited by

See all 336

Metadata

Authors
Rathmell, W. K., Rumble, R. B., Van Veldhuizen, P. J., Al-Ahmadie, H., Emamekhoo, H., Hauke, R. J., Louie, A. V., Milowsky, M. I., Molina, A. M., Rose, T. L., Siva, S., Zaorsky, N. G., Zhang, T., Qamar, R., Kungel, T. M., Lewis, B., & Singer, E. A.
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2022-09-01
Volume
40
Issue
25
Pages
2957-2995
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.22.00868
OpenAlex
W4283220315
Cited by
336
References
120
FWCI
38.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. https://app.cochat.ai/papers/10.1200/jco.22.00868
The paper
Rathmell, W. K., Rumble, R. B., Van Veldhuizen, P. J., Al-Ahmadie, H., Emamekhoo, H., Hauke, R. J., Louie, A. V., Milowsky, M. I., Molina, A. M., Rose, T. L., Siva, S., Zaorsky, N. G., Zhang, T., Qamar, R., Kungel, T. M., Lewis, B., & Singer, E. A. (2022). Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.00868

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.